Photodynamic therapy with verteporfin in ocular histoplasmosis: Uncontrolled, open-label 2-year study

Philip J Rosenfeld, David A. Saperstein, Neil M. Bressler, Troy A. Reaves, Michel Sickenberg, Robert H. Rosa, Paul Sternberg, Thomas M. Aaberg, Thomas M. Aaberg

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Objective To evaluate the safety, effect on visual function, and fluorescein angiographic appearance of subfoveal choroidal neovascularization (CNV) through 2 years after photodynamic therapy with verteporfin (Visudyne; Novartis AG, Basel, Switzerland) in patients with ocular histoplasmosis syndrome (OHS). Design Open-label, 3-center, uncontrolled clinical study. Participants Ocular histoplasmosis syndrome patients with subfoveal CNV (N = 26) with a greatest linear dimension no larger than 5400 μm with classic or occult CNV extending under the geometric center of the fovea, and best-corrected visual acuity letter score of approximately 20/40 to 20/200. Methods The methods were similar to those described in the 1-year results with follow-up examinations every 3 months continuing through the second year. During the second year, additional therapy was recommended if fluorescein angiography showed leakage at a scheduled visit. Main outcome measurements Visual function measurements included the changes from baseline in visual acuity and contrast sensitivity scores. Lesion size and leakage from classic and occult CNV were assessed at month 12 and month 24. Safety assessments also were made. Results A 24-month examination was completed in 22 of the 26 enrolled participants (85%). At the 24-month examination, median improvement from baseline in visual acuity of the 22 patients evaluated was 6 letters; median contrast sensitivity improved by 3.5 letters. At the 24-month examination, 10 patients (45%) gained 7 or more letters of visual acuity from baseline, whereas 4 patients (18%) lost 8 or more letters, including 2 patients (9%) who lost at least 15 letters. There was absence of fluorescein angiographic leakage from classic CNV in 17 of the 20 evaluable lesions (85%), and leakage from occult CNV was absent in all eyes. No serious ocular adverse events were reported, and no serious systemic event was considered to be associated with treatment. Conclusions Median visual acuity improved and fluorescein angiographic leakage decreased after verteporfin therapy in this small, uncontrolled clinical study of patients with subfoveal CNV resulting from OHS. Verteporfin therapy seemed to be relatively safe in these patients. The selected cases feature fluorescein angiographic examples of CNV that are important in determining when to apply verteporfin therapy.

Original languageEnglish
Pages (from-to)1725-1733
Number of pages9
JournalOphthalmology
Volume111
Issue number9
DOIs
StatePublished - Sep 1 2004

Fingerprint

Histoplasmosis
Choroidal Neovascularization
Photochemotherapy
Visual Acuity
Fluorescein
Contrast Sensitivity
Therapeutics
Safety
verteporfin
Fluorescein Angiography
Switzerland

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Rosenfeld, P. J., Saperstein, D. A., Bressler, N. M., Reaves, T. A., Sickenberg, M., Rosa, R. H., ... Aaberg, T. M. (2004). Photodynamic therapy with verteporfin in ocular histoplasmosis: Uncontrolled, open-label 2-year study. Ophthalmology, 111(9), 1725-1733. https://doi.org/10.1016/j.ophtha.2004.02.014

Photodynamic therapy with verteporfin in ocular histoplasmosis : Uncontrolled, open-label 2-year study. / Rosenfeld, Philip J; Saperstein, David A.; Bressler, Neil M.; Reaves, Troy A.; Sickenberg, Michel; Rosa, Robert H.; Sternberg, Paul; Aaberg, Thomas M.; Aaberg, Thomas M.

In: Ophthalmology, Vol. 111, No. 9, 01.09.2004, p. 1725-1733.

Research output: Contribution to journalArticle

Rosenfeld, PJ, Saperstein, DA, Bressler, NM, Reaves, TA, Sickenberg, M, Rosa, RH, Sternberg, P, Aaberg, TM & Aaberg, TM 2004, 'Photodynamic therapy with verteporfin in ocular histoplasmosis: Uncontrolled, open-label 2-year study', Ophthalmology, vol. 111, no. 9, pp. 1725-1733. https://doi.org/10.1016/j.ophtha.2004.02.014
Rosenfeld, Philip J ; Saperstein, David A. ; Bressler, Neil M. ; Reaves, Troy A. ; Sickenberg, Michel ; Rosa, Robert H. ; Sternberg, Paul ; Aaberg, Thomas M. ; Aaberg, Thomas M. / Photodynamic therapy with verteporfin in ocular histoplasmosis : Uncontrolled, open-label 2-year study. In: Ophthalmology. 2004 ; Vol. 111, No. 9. pp. 1725-1733.
@article{ee6547b6efb0457a91e08b9a5ae860b3,
title = "Photodynamic therapy with verteporfin in ocular histoplasmosis: Uncontrolled, open-label 2-year study",
abstract = "Objective To evaluate the safety, effect on visual function, and fluorescein angiographic appearance of subfoveal choroidal neovascularization (CNV) through 2 years after photodynamic therapy with verteporfin (Visudyne; Novartis AG, Basel, Switzerland) in patients with ocular histoplasmosis syndrome (OHS). Design Open-label, 3-center, uncontrolled clinical study. Participants Ocular histoplasmosis syndrome patients with subfoveal CNV (N = 26) with a greatest linear dimension no larger than 5400 μm with classic or occult CNV extending under the geometric center of the fovea, and best-corrected visual acuity letter score of approximately 20/40 to 20/200. Methods The methods were similar to those described in the 1-year results with follow-up examinations every 3 months continuing through the second year. During the second year, additional therapy was recommended if fluorescein angiography showed leakage at a scheduled visit. Main outcome measurements Visual function measurements included the changes from baseline in visual acuity and contrast sensitivity scores. Lesion size and leakage from classic and occult CNV were assessed at month 12 and month 24. Safety assessments also were made. Results A 24-month examination was completed in 22 of the 26 enrolled participants (85{\%}). At the 24-month examination, median improvement from baseline in visual acuity of the 22 patients evaluated was 6 letters; median contrast sensitivity improved by 3.5 letters. At the 24-month examination, 10 patients (45{\%}) gained 7 or more letters of visual acuity from baseline, whereas 4 patients (18{\%}) lost 8 or more letters, including 2 patients (9{\%}) who lost at least 15 letters. There was absence of fluorescein angiographic leakage from classic CNV in 17 of the 20 evaluable lesions (85{\%}), and leakage from occult CNV was absent in all eyes. No serious ocular adverse events were reported, and no serious systemic event was considered to be associated with treatment. Conclusions Median visual acuity improved and fluorescein angiographic leakage decreased after verteporfin therapy in this small, uncontrolled clinical study of patients with subfoveal CNV resulting from OHS. Verteporfin therapy seemed to be relatively safe in these patients. The selected cases feature fluorescein angiographic examples of CNV that are important in determining when to apply verteporfin therapy.",
author = "Rosenfeld, {Philip J} and Saperstein, {David A.} and Bressler, {Neil M.} and Reaves, {Troy A.} and Michel Sickenberg and Rosa, {Robert H.} and Paul Sternberg and Aaberg, {Thomas M.} and Aaberg, {Thomas M.}",
year = "2004",
month = "9",
day = "1",
doi = "10.1016/j.ophtha.2004.02.014",
language = "English",
volume = "111",
pages = "1725--1733",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",
number = "9",

}

TY - JOUR

T1 - Photodynamic therapy with verteporfin in ocular histoplasmosis

T2 - Uncontrolled, open-label 2-year study

AU - Rosenfeld, Philip J

AU - Saperstein, David A.

AU - Bressler, Neil M.

AU - Reaves, Troy A.

AU - Sickenberg, Michel

AU - Rosa, Robert H.

AU - Sternberg, Paul

AU - Aaberg, Thomas M.

AU - Aaberg, Thomas M.

PY - 2004/9/1

Y1 - 2004/9/1

N2 - Objective To evaluate the safety, effect on visual function, and fluorescein angiographic appearance of subfoveal choroidal neovascularization (CNV) through 2 years after photodynamic therapy with verteporfin (Visudyne; Novartis AG, Basel, Switzerland) in patients with ocular histoplasmosis syndrome (OHS). Design Open-label, 3-center, uncontrolled clinical study. Participants Ocular histoplasmosis syndrome patients with subfoveal CNV (N = 26) with a greatest linear dimension no larger than 5400 μm with classic or occult CNV extending under the geometric center of the fovea, and best-corrected visual acuity letter score of approximately 20/40 to 20/200. Methods The methods were similar to those described in the 1-year results with follow-up examinations every 3 months continuing through the second year. During the second year, additional therapy was recommended if fluorescein angiography showed leakage at a scheduled visit. Main outcome measurements Visual function measurements included the changes from baseline in visual acuity and contrast sensitivity scores. Lesion size and leakage from classic and occult CNV were assessed at month 12 and month 24. Safety assessments also were made. Results A 24-month examination was completed in 22 of the 26 enrolled participants (85%). At the 24-month examination, median improvement from baseline in visual acuity of the 22 patients evaluated was 6 letters; median contrast sensitivity improved by 3.5 letters. At the 24-month examination, 10 patients (45%) gained 7 or more letters of visual acuity from baseline, whereas 4 patients (18%) lost 8 or more letters, including 2 patients (9%) who lost at least 15 letters. There was absence of fluorescein angiographic leakage from classic CNV in 17 of the 20 evaluable lesions (85%), and leakage from occult CNV was absent in all eyes. No serious ocular adverse events were reported, and no serious systemic event was considered to be associated with treatment. Conclusions Median visual acuity improved and fluorescein angiographic leakage decreased after verteporfin therapy in this small, uncontrolled clinical study of patients with subfoveal CNV resulting from OHS. Verteporfin therapy seemed to be relatively safe in these patients. The selected cases feature fluorescein angiographic examples of CNV that are important in determining when to apply verteporfin therapy.

AB - Objective To evaluate the safety, effect on visual function, and fluorescein angiographic appearance of subfoveal choroidal neovascularization (CNV) through 2 years after photodynamic therapy with verteporfin (Visudyne; Novartis AG, Basel, Switzerland) in patients with ocular histoplasmosis syndrome (OHS). Design Open-label, 3-center, uncontrolled clinical study. Participants Ocular histoplasmosis syndrome patients with subfoveal CNV (N = 26) with a greatest linear dimension no larger than 5400 μm with classic or occult CNV extending under the geometric center of the fovea, and best-corrected visual acuity letter score of approximately 20/40 to 20/200. Methods The methods were similar to those described in the 1-year results with follow-up examinations every 3 months continuing through the second year. During the second year, additional therapy was recommended if fluorescein angiography showed leakage at a scheduled visit. Main outcome measurements Visual function measurements included the changes from baseline in visual acuity and contrast sensitivity scores. Lesion size and leakage from classic and occult CNV were assessed at month 12 and month 24. Safety assessments also were made. Results A 24-month examination was completed in 22 of the 26 enrolled participants (85%). At the 24-month examination, median improvement from baseline in visual acuity of the 22 patients evaluated was 6 letters; median contrast sensitivity improved by 3.5 letters. At the 24-month examination, 10 patients (45%) gained 7 or more letters of visual acuity from baseline, whereas 4 patients (18%) lost 8 or more letters, including 2 patients (9%) who lost at least 15 letters. There was absence of fluorescein angiographic leakage from classic CNV in 17 of the 20 evaluable lesions (85%), and leakage from occult CNV was absent in all eyes. No serious ocular adverse events were reported, and no serious systemic event was considered to be associated with treatment. Conclusions Median visual acuity improved and fluorescein angiographic leakage decreased after verteporfin therapy in this small, uncontrolled clinical study of patients with subfoveal CNV resulting from OHS. Verteporfin therapy seemed to be relatively safe in these patients. The selected cases feature fluorescein angiographic examples of CNV that are important in determining when to apply verteporfin therapy.

UR - http://www.scopus.com/inward/record.url?scp=4444295827&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4444295827&partnerID=8YFLogxK

U2 - 10.1016/j.ophtha.2004.02.014

DO - 10.1016/j.ophtha.2004.02.014

M3 - Article

C2 - 15350329

AN - SCOPUS:4444295827

VL - 111

SP - 1725

EP - 1733

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

IS - 9

ER -